Vaccines and melanoma

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

2001 • 2,658 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

Progress in human tumour immunology and immunotherapy

2001 • 1,327 citations

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

1999 • 1,260 citations

Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance

1999 • 1,168 citations

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

2001 • 905 citations

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1

1999 • 803 citations

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

2000 • 500 citations

Dendritic cells: On the move from bench to bedside

2001 • 291 citations

Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation.

2001 • 215 citations

Surgical Adjuvant Active Specific Immunotherapy for Patients with Stage III Melanoma: The Final Analysis of Data from a Phase III, Randomized, Double-Blind, Multicenter Vaccinia Melanoma Oncolysate Trial

1998 • 183 citations

Tumor antigens recognized by T lymphocytes

1997 • 153 citations

Development of Cancer Immunotherapies Based on Identification of the Genes Encoding Cancer Regression Antigens

1996 • 132 citations

Perspective on allogeneic melanoma lysates in active specific immunotherapy.

1998 • 113 citations

Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.

2001 • 100 citations

Active immunotherapy with allogeneic tumor cell vaccines: present status.

1998 • 89 citations

MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.

1997 • 89 citations

Vaccination for Malignant Melanoma: Recent Developments

2000 • 80 citations

New perspectives on immunobiology and immunotherapy of melanoma

1999 • 65 citations

The evolution of gastrointestinal endoscopy at the Mount Sinai Hospital.

2001 • 48 citations

Adjuvant therapy of melanoma

1998 • 47 citations

Autologous, hapten-modified vaccine as a treatment for human cancers

2001 • 42 citations

Cell-based vaccination against melanoma – background, preliminary results, and perspective

1999 • 39 citations

Immune Monitoring in Cancer Immunotherapy

2000 • 7 citations